Prot# N01315: An Open-Label, Multinational, Multicenter, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam, Used at a Flexible Dose Up to a Maximum of 150 mg/day, in Subjects Aged 16 Years of Older Suffering from Epilepsy